CADL
Candel Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.21
+0.24%Sep 30, 2026, 12:05 UTC
Candel Therapeutics presented new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec in patients with localized intermediate- to high-risk prostate cancer at the ASTRO Annual Meeting 2026.
Source:Sep 21, 2026, 14:04 UTC
Candel Therapeutics shares rose 7.56% to $11.67 after an analyst upgraded the stock to Buy and raised the price target to $18 from $12.
Source:Sep 10, 2026, 12:22 UTC
Candel Therapeutics, Inc. appointed Martine Zimmermann as a director, effective September 8, 2026.
Aug 13, 2026, 12:05 UTC
Candel Therapeutics announced its financial results for the second quarter ended June 30, 2026.
Source:Jun 30, 2026, 12:05 UTC
Candel Therapeutics initiated a global pivotal Phase 3 AURORA trial evaluating aglatimagene besadenovec (CAN-2409) in advanced non-small cell lung cancer patients with inadequate response to immune checkpoint inhibitors.
Source:Jun 1, 2026, 20:05 UTC
Candel Therapeutics granted stock options to three new employees on May 31, 2026.